CD274 and melanoma: Blockage of PD‐1/PD‐L1 can thus enhance T cell activity and restore antitumor immunity.7 In clinical practice, PD‐1/PD‐L1 expression intensity has been shown to be associated with the clinical benefit in various tumor types including as NSCLC8 and melanoma.9 In recent years, PD‐1 inhibitors such as pembrolizumab and nivolumab, as well as PD‐L1 inhibitor atezolizumab have been approved for the treatment of several tumor types including NSCLC.